Amyris, Inc.
INVESTOR PRESENTATION September 2020
Amyris, Inc. INVESTOR PRESENTATION September 2020 Investor - - PowerPoint PPT Presentation
Amyris, Inc. INVESTOR PRESENTATION September 2020 Investor Presentation | September 2020 FORWARD LOOKING STATEMENT This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other
INVESTOR PRESENTATION September 2020
This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected revenue, including revenues from consumer, ingredients, collaboration & grants, recurring revenue, EBITDA, gross profit, gross margin and operating expenses in 2020, including related growth rates, anticipated growth for Amyris’s businesses, expected debt reduction in 2020, and expectations regarding Amyris’s financial and operational results and ability to achieve its business plan in 2020 and beyond. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production or commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. NON-GAAP FINANCIAL INFORMATION This presentation and oral statements accompanying this presentation contain both GAAP and non-GAAP financial information. Amyris considers non-GAAP financial information to be a helpful measure to assess its operational performance and for financial and operational decision-making.
Totals in this presentation may not foot due to rounding.
Investor Presentation | September 2020
molecules driving speed to market and enabling deep strategic partnerships
brands disrupting the beauty space
fragrance, and health and wellness end-markets
2019 GROSS MARGIN (NON-GAAP)
Strong growth prospects driven by consumer megatrends and underpinned by proprietary science
Page 3
64 153
$0 $20 $40 $60 $80 $100 $120 $140 $160 $180
FY 2018 FY 2019
FY 2018-2019 Sales
+140%
($ in millions)
Investor Presentation | September 2020
Leadership Team Board of Directors
Geoffrey Duyk M.D., Ph.D Partner, Circularis Partners Philip Eykerman EVP, Corp Strategy & Acquisitions, DSM Christoph Goppelsroeder President and CEO, DSM Nutritional products
Founding Member, Vivo Capital James McCann Founder and Chairman, 1-800-FLOWERS.COM John Melo President & CEO, Amyris Steve Mills Former CFO, ADM and Amyris Carole Piwnica Director, Sanofi/ Director, Rothschild / Chairman, Arianna S.A. Lisa Qi Director, Daling Family/GM YSL China Julie Spencer Washington Chief Marketing & Communications Officer, Trinity Health Patrick Yang Ph.D. EVP, Juno Therapeutics/SVP Operations Roche/EVP Operations Genentech
Page 4
Daya Fields President, Pipette & Purecane
H.C. Wainwright Investor Conference | September 14, 2020
Beauty (Skin Care + Baby) Flavors & Fragrance Alternative Sweeteners
200 48 $Billion
Addressable Market
Key Technical Metrics Molecules commercialized per year ~2-4 Number of PhD’s ~85 Number of US and foreign patents issued and applications pending 871 Molecules Manufactured 10 Pipeline of molecules in development 17
9
Growth markets that are accelerated by Consumers push for Health, Clean and Sustainable
standard in beauty
clear direction
taste and mouthfeel is a winner
Page 5 From First Strain to First Pilot Run (2012-2019)
Investor Presentation | September 2020
1 Based on preliminary unaudited Q1 2020 performance 2 BiossanceTM, PipetteTM, PurecaneTM 3 Flavors and Fragrance, Natural Sweeteners, Personal and Home Care
Sales by Geography
Consumer & Ingredients Collaboration & Grants
76% 24% Sales1
Consumer2 36% Ingredients3 40%
North America EU and UK Asia Latin America
47% 19% 28%
6%
Sales by Category Sales by End Markets
Clean Skin Care Health Flavors Perfumes Personal and Home Care
39% 24% 29%
4% 4%
Page 6
Sales1 Sales1
Investor Presentation | September 2020
World’s leading synthetic biology platform The world’s leading synthetic biology platform. Nine commercialized products delivering the most profitable and fastest growing revenue in synthetic biology High growth Clean Beauty consumer brands Our Biossance & Pipette Clean Skin Care brands are the fastest growing in North America – 2019 Revenue of $17m growing >300% YOY Clean and safe ingredients are more important than ever before Our growth is accelerating through COVID-19. Consumers are transitioning to clean and safe ingredients faster than ever and we are a leading supplier with advantaged technology
Proprietary functional ingredients Our ingredients are inside over $10B of consumer purchases sold through 3,000+
The #1 Supplier of Clean, Sustainable ingredients to Leading Brands Owner of the Leading Clean Health and Beauty Brands in North America
Page 7
Investor Presentation | September 2020
We have defined the Gold Standard for Clean Chemistry
Iteration cycles measured in minutes rather than weeks
Industrialized Synthetic Biology delivery in 12 months
Page 8
Dedicated pipeline: Automated Scientist and state-of-the-art robotics
Investor Presentation | September 2020
We Partner with Market Leaders Owned Brands set the Standard for Consumers #1 Producer of Clean Ingredients
The #1 Supplier of Natural and Sustainably sourced Platform Molecules The #1 Supplier of Natural and Sustainably sourced Platform Molecules
EXISTING PIPELINE
*Confidential products **Recurring revenue includes all revenue that has a multiyear contract and revenue from our consumer brands Page 9
On track for third consecutive year of doubling recurring revenue**
Investor Presentation | September 2020
High growth consumer brands
Scientific and commercial collaboration
Supply chain optimization
Improved balance sheet, earnings and cash flow
Page 10
performance
Driving a multi-faceted agenda to deliver value for consumers, partners and shareholders
Investor Presentation | September 2020
Return on Advertising Spend: Q3 2019: $3.76 Q4 2019: $5.43 Q1 2020: $9.20
Page 11
Investor Presentation | September 2020
Page 12
FOUNDER We originate from… SOURCE We source from… IDENTITY We are… PERSONALITY We act… PRODUCT We make…
BERKELEY BIOTECHNOLOGY BRAZILIAN SUGARCANE APPROACHABLE SCIENCE SELFLESS EDUCATION CLEAN-ICAL
(Equally clinical & clean)
Investor Presentation | September 2020
Page 13
Clean Academy Leader in Clean Beauty education
City Takeover 360 Takeovers, including NYC and LA
Become the most loyal brand With the most passionate followers
Digital Leadership Best in class experience, engagement and platforms
Biossance Brand Key Initiatives
Investor Presentation | September 2020
15 26 40 62 97 127 154 194 222 237 250 299
2017-Q1 2017-Q2 2017-Q3 2017-Q4 2018-Q1 2018-Q2 2018-Q3 2018-Q4 2019-Q1 2019-Q2 2019-Q3 2019-Q4
2017-2019 CAGR = ~350%
TOTAL # OF BIOSSANCE.COM CUSTOMERS (000’s)
Biossance Key Growth Drivers
Dec 2018 = 104% June 2019 = 141% Dec 2019 = 135% Jan 2020 = 205%
2019 YE: in all 460 Sephora NA stores 2020: will participate in Sephora NA’s 100 new store openings
SALES
Sephora Monthly Productivity*
*Sephora Productivity is how Biossance performs compared to its peers in revenue per square foot per month
113 130 240 297 296 255
2017 2019YE 2018
EC (17 SKUs) Wall (6SKUs)
DOORS
Sephora End Caps produces 2-2.5X more retail revenue
Page 14
Investor Presentation | September 2020
Launched September 4, 2019
Retail Channel Distribution
Page 15
Investor Presentation | May 2020
Leading “Clean” Brand Leading “Conventional” Brand
EWG Verified Dermatologist Tested Pediatrician Approved Hypoallergenic Vegan Tear Free Sulfate Free PEG Free Mineral Oil/Petrolatum Free Synthetic Fragrance Free Silicone Free
Page 16
Investor Presentation | September 2020
Page 17
Brought new Pipette branded hand sanitizer to market in April in 10 days Brought new Pipette branded hand sanitizer to market in April in 10 days
Investor Presentation | September 2020
cleaning and personal care products
has shifted to internet purchasing
Page 18
Investor Presentation | September 2020
Page 19
higher revenue from scale-up products (contributing low margins)
Recurring revenue of $30 million grew 36% YoY and 23% QoQ
DEBT REDUCTION DURING H1
GROSS MARGIN (NON-GAAP)
YOY RECURRING REVENUE
LOWEST IN 5 QUARTERS Investor Presentation | September 2020
Page 20
Total Sales Revenue $m (Recurring vs one-off) 15 22 35 32 24 30
5
Q119 Q219 Q319 Q419 Q120 Q220 Sales Revenue ($m) excl one-offs One-off items ($m)
63 41 29
continued growth YoY (+36%) and QoQ (+23%)
with revenue of $26m, up 111% YoY. Consumer sales tripled YoY from strong
revenue generated from product sales (Consumer & Ingredients at 87%) versus Collaboration programs (13%)
Recurring Revenue $m Collaboration vs Consumer & Ingredients 12 12 20 20 19 26 2 10 15 11 5 4
0.05 0.1 0.15 0.2 0.25 $0 $5 $10 $15 $20 $25 $30 $35 $40Q119 Q219 Q319 Q419 Q120 Q220 Consumer & Ingredients ($m) excl one-offs Collaboration & Grants ($m)
30 15 22 35 24 32 Investor Presentation | September 2020
Page 21
12/31/19 03/31/20
06/30/20
Common outstanding 117.7m 163.9m
204.6m
Fully diluted shares 214.2m 252.1m
278.8m
Market capitalization $364m $420m
$874m
Total capitalization $661m $629m $1,051m
Capitalization
Breakdown of fully diluted shares 06/30/20 Common outstanding 204.6m Warrants (details in appendix) 49.5m Preferred and converts 10.5m Employee stock plans 14.2m Fully diluted shares 278.8m 297 209 177
$0 $50 $100 $150 $200 $250 $300 $350
12/31/19 03/31/20 6/30/2020
Total Debt
($ Millions)
Reduced debt by 40% during H1 2020
Investor Presentation | September 2020
Key Investment Highlights
approach to high value chemistry for a sustainable planet
Clean Beauty, Natural Health and Natural Flavor and Fragrance Ingredients
scaling technology and our market position to accelerate sector leadership
Page 22
Investor Presentation | September 2020
Good for People Good for the Planet Good for Business
Page 23
Investor Presentation | September 2020